Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced the signing of a definitive agreement to acquire Hint, Inc., a privately held company doing business under the name HintMD, which has created an integrated financial technology (fintech) platform for the aesthetics industry. The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions, including receipt of approval of the requisite HintMD stockholders.
Read the full article: Revance Announces Agreement to Acquire HintMD and Its Proprietary Fintech Platform for Aesthetic Practices //
Source: https://www.businesswire.com/news/home/20200519005316/en/Revance-Announces-Agreement-Acquire-HintMD-Proprietary-Fintech